IBA - DATA CONCERNING TRANSPARENCY
Louvain-la-Neuve, Belgium, March 2, 2015 - IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received on February 27, 2015 a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008), the content of which is summarized below.
Further to the capital increase of February 26, 2015(exercise of stock options), the holding of Institut des Radio-Eléments (IRE) FUP has been passively, due to the dilutive effect, brought below the 5% threshold. IRE is not controlled in the meaning of Article 5 of the Company Code.
| Entity | shares (%) with voting rights 31 décembre 2014 Denominator = 28 393 804 | shares (%) with voting rights 26 February 2015 denominator =28 653 520 |
| IRE FUP Zoning Industriel Avenue de l'Esperance 1 6220 Fleurus | 1 423 271 (5.01%) | 1 423 271 (4.97%) |
* * *
*
About IBA
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
Headquartered in Belgium and employing more than 1,100 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.
IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
For more information, please contact
IBA
Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com
